Detalhe da pesquisa
1.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 388(11): 1002-1014, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762851
2.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Cancer
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630908
3.
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1D): e240001, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244272
4.
Update on the current and future use of CAR-T to treat multiple myeloma.
Eur J Haematol
; 112(4): 493-503, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38099401
5.
Infective endocarditis is rare in patients with hematologic malignancy and neutropenia.
Transpl Infect Dis
; : e14302, 2024 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38761053
6.
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651976
7.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
8.
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Br J Haematol
; 203(5): 736-746, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287117
9.
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.
Blood
; 137(1): 61-74, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640012
10.
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(1): 67-81, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652935
11.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(12): 1281-1301, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38081133
12.
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
Am J Hematol
; 98(1): 140-147, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567778
13.
The Management of Relapsed and Refractory Multiple Myeloma.
Oncology (Williston Park)
; 37(4): 164-174, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37104757
14.
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Br J Cancer
; 126(5): 718-725, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34802051
15.
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
J Natl Compr Canc Netw
; 20(1): 91-95, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991076
16.
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
J Natl Compr Canc Netw
; 20(1): 8-19, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991075
17.
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
Am J Hematol
; 97(9): 1170-1177, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731911
18.
Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
Transpl Infect Dis
; 24(2): e13792, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030267
19.
Clinical effects and applications of the gut microbiome in hematologic malignancies.
Cancer
; 127(5): 679-687, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369893
20.
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer
; 127(22): 4198-4212, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314018